Acrivon director granted 20,275 stock options

Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares remain held following the grant. The option will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, conditioned on Santhosh’s continuous service through that vesting date.

Insider Trade Summary

Grant/Award: 20,275 shares

Grant/Award 1 txn

Insider Palani Santhosh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,275	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,275 contracts (Direct)

Footnotes (1)

F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Options granted: 20,275 shares Exercise price: $1.52 per share Expiration date: June 16, 2036 +1 more

4 metrics

Options granted 20,275 shares Stock Option (Right to Buy) grant on June 17, 2026

Exercise price $1.52 per share Conversion or exercise price of stock option grant

Expiration date June 16, 2036 Option expiration for 20,275-share grant

Total options held after grant 20,275 shares Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.5200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders regulatory

"shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through the applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) director Palani Santhosh report in this Form 4?

Palani Santhosh reported receiving a stock option grant for 20,275 shares of Acrivon Therapeutics common stock. The filing reflects a compensation-related award, not an open-market purchase or sale, and shows these options as directly held following the transaction.

What is the exercise price and size of the ACRV stock option grant to Palani Santhosh?

The stock option grant covers 20,275 shares of Acrivon Therapeutics common stock with an exercise price of $1.52 per share. This means Santhosh can buy those shares at $1.52 once the options vest, subject to the specified vesting conditions.

When do the stock options granted to ACRV director Palani Santhosh expire?

The stock options granted to Palani Santhosh expire on June 16, 2036. After that date, any unexercised portion of the 20,275-share option grant can no longer be used to purchase Acrivon Therapeutics common stock at the $1.52 exercise price.

What are the vesting conditions for Palani Santhosh’s Acrivon Therapeutics stock options?

The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on Santhosh’s continuous service with the company through that vesting date, so leaving earlier would typically prevent the award from vesting.

Did Palani Santhosh buy or sell ACRV shares in the market in this Form 4?

No open-market buy or sell occurred; the Form 4 reports a grant of stock options as compensation. The transaction is coded as an acquisition (grant/award) of derivative securities, with 20,275 option shares held directly after the grant, rather than a cash market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palani Santhosh

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.52	06/17/2026		A		20,275		⁽¹⁾	06/16/2036	Common Stock	20,275	$0	20,275	D

Explanation of Responses:

1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR